CH
NMTR

CVI Holdings’s 9 Meters Biopharma NMTR Stock Holding History

CVI Holdings’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-106,723
Closed -$2.5M – 855
2021
Q1 		$2.5M Buy
+106,723
New +$3.28M 0.17% 186

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings's NMTR Position: Q2 2021 in Review

CVI Holdings sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 106,723 shares — an estimated $2.5M sold.

CVI Holdings first reported a position in NMTR in Q1 2021 and held it in 1 quarter. The position peaked at $2.5M in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

  • CVI Holdings reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
  • CVI Holdings sold 106,723 9 Meters Biopharma shares in Q2 2021, an estimated $2.5M.
  • CVI Holdings first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 1 quarter.
  • CVI Holdings's 9 Meters Biopharma position peaked at $2.5M in Q1 2021.
  • 99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on CVI Holdings's 13F filing for Q2 2021, filed 11 Aug 2021.